These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1309050)

  • 1. In vitro diagnosis of fibrinolysis: present status and desired improvements.
    Kluft C
    Ann N Y Acad Sci; 1992 Dec; 667():291-304. PubMed ID: 1309050
    [No Abstract]   [Full Text] [Related]  

  • 2. Impaired capacity for endogenous fibrinolysis in essential hypertension.
    Hrafnkelsdóttir T; Wall U; Jern C; Jern S
    Lancet; 1998 Nov; 352(9140):1597-8. PubMed ID: 9843110
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of venous occlusion on fibrinolytic potential and plasma storage at -20 degrees C or -70 degrees C.
    Monte G; Melissari E; Kakkar VV
    Recenti Prog Med; 1993 Jun; 84(6):435-7. PubMed ID: 8516552
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of endothelin on the release of tissue plasminogen activator and plasminogen activator inhibitor-1 from cultured human endothelial cells and interaction with thrombin.
    Yamamoto C; Kaji T; Sakamoto M; Koizumi F
    Thromb Res; 1992 Sep; 67(5):619-24. PubMed ID: 1448794
    [No Abstract]   [Full Text] [Related]  

  • 5. Association between sympathoadrenal activation, fibrinolysis, and endothelial damage in septic patients: a prospective study.
    Johansson PI; Haase N; Perner A; Ostrowski SR
    J Crit Care; 2014 Jun; 29(3):327-33. PubMed ID: 24581948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of local availability of active tissue-type plasminogen activator in vivo in man.
    Hrafnkelsdottir T; Gudnason T; Wall U; Jern C; Jern S
    J Thromb Haemost; 2004 Nov; 2(11):1960-8. PubMed ID: 15550028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulators of fibrynolysis in plasma of kidney transplant recipients.
    Perkowska A; Elhasade A; Gaciong Z; Durlik M; Placha G; Galazka Z; Lao M
    Transplant Proc; 2002 Mar; 34(2):585-8. PubMed ID: 12009632
    [No Abstract]   [Full Text] [Related]  

  • 8. Retinoids and fibrinolysis.
    Bäck O; Nilsson TK
    Acta Derm Venereol; 1995 Jul; 75(4):290-2. PubMed ID: 8578951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of specific hormones on fibrinolysis in pregnancy.
    Houlihan CM; Knuppel RA; Vintzileos AM; Guo JZ; Hahn DW
    Am J Obstet Gynecol; 1996 Jul; 175(1):168-72. PubMed ID: 8694045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome.
    Lindholm A; Bixo M; Eliasson M; Hudecova M; Arnadottir R; Holte J; Poromaa IS
    Gynecol Endocrinol; 2010 Oct; 26(10):743-8. PubMed ID: 20500107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial fibrinolytic function in hypertension: the expanding story.
    Oliver JJ; Newby DE
    J Hypertens; 2005 Aug; 23(8):1471-2. PubMed ID: 16003171
    [No Abstract]   [Full Text] [Related]  

  • 12. Release of tissue plasminogen activator during coronary angioplasty.
    Weyne A; de Buyzere M; Clement D; Baele G; Leroux-Roels G
    Lancet; 1990 Mar; 335(8690):658. PubMed ID: 1969029
    [No Abstract]   [Full Text] [Related]  

  • 13. Altered endothelial function following the Fontan procedure.
    Binotto MA; Maeda NY; Lopes AA
    Cardiol Young; 2008 Feb; 18(1):70-4. PubMed ID: 18093358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrin-specific fibrinolysis.
    Collen D; Lijnen HR
    Ann N Y Acad Sci; 1992 Dec; 667():259-71. PubMed ID: 1285022
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationship of urokinase type plasminogen activator, plasminogen activator inhibitor type 1 and activated protein C in fibrinolysis of human placenta.
    Moniwa N
    Pol J Pharmacol; 1996; 48(2):215-20. PubMed ID: 9112654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Levels of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Are Independent Predictors of Coronavirus Disease 2019 Severity: A Prospective, Observational Study.
    Henry BM; Cheruiyot I; Benoit JL; Lippi G; Prohászka Z; Favaloro EJ; Benoit SW
    Semin Thromb Hemost; 2021 Jun; 47(4):451-455. PubMed ID: 33482678
    [No Abstract]   [Full Text] [Related]  

  • 17. Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers: smoking, thrombin, and vascular responses in vivo.
    Lang NN; Gudmundsdóttir IJ; Boon NA; Ludlam CA; Fox KA; Newby DE
    J Am Coll Cardiol; 2008 Jul; 52(1):33-9. PubMed ID: 18582632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes in plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) by the interferon treatment for chronic hepatitis C].
    Hayashi T; Ro S; Kamogawa A; Kobayashi Y; Suzuki Y; Imai M; Okuse C; Ozaki M; Iwabuchi S; Murayama M
    Rinsho Byori; 1995 Sep; 43(9):948-52. PubMed ID: 7474459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exercise training enhances endogenous fibrinolysis in peripheral arterial disease.
    Killewich LA; Macko RF; Montgomery PS; Wiley LA; Gardner AW
    J Vasc Surg; 2004 Oct; 40(4):741-5. PubMed ID: 15472603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease.
    de Bono D
    Br Heart J; 1994 Jun; 71(6):504-7. PubMed ID: 8043326
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.